Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Pivotal bioVenture Partners

Investor type Venture Capital
Founders Tracy Saxton

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 28
Average round size
info
The average size of a deal this fund participated in
$86M
Portfolio companies 22
Rounds per year 5.60
Lead investments 6
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.21
Exits 11
Key employees 3
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Pharmaceutical
  • Health Care
  • Medical
  • Therapeutics
Summary

Pivotal bioVenture Partners appeared to be the VC, which was created in 2017. The main department of described VC is located in the San Francisco. The venture was found in North America in United States.

We can highlight the next thriving fund investment areas, such as Medical, Pharmaceutical. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in a number of founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Among the most popular portfolio startups of the fund, we may highlight Fusion Pharmaceuticals, SutroVax, Bolt Biotherapeutics. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.

The current fund was established by Tracy Saxton. We also calculated 3 valuable employees in our database.

The higher amount of exits for fund were in 2019. The fund is constantly included in 2-6 deals per year. Speaking about the real fund results, this VC is 36 percentage points more often commits exit comparing to other organizations. Deals in the range of 50 - 100 millions dollars are the general things for fund. The important activity for fund was in 2019. This Pivotal bioVenture Partners works on 15 percentage points more the average amount of lead investments comparing to the other organizations.

The standard case for the fund is to invest in rounds with 7-8 partakers. Despite the Pivotal bioVenture Partners, startups are often financed by Frazier Healthcare Partners, Wellcome Trust, Technology Development Fund. The meaningful sponsors for the fund in investment in the same round are Sofinnova Investments, Vivo Capital, Frazier Healthcare Partners. In the next rounds fund is usually obtained by Tekla Capital Management, TPG Growth, Roche Venture Fund.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Pivotal bioVenture Partners:
Typical Co-investors
Pivotal bioVenture Partners is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Pivotal bioVenture Partners:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Benson Capital -
Blue Bear Capital Beverly Hills, California, United States
Hill-Rom Batesville, Indiana, United States
INTEC Japan, Okinawa Prefecture, Toyama
JustSystems British Columbia, Canada, Vancouver
Laurentian Bank Securities -
Omphalos Ventures India. -
Physician Partners Florida, Ocala, United States
Shangkun Investment China, Hangzhou, Zhejiang
State Farm Insurance Bloomington, Illinois, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Plexium

Biotechnology
Health Care
Medical
Pharmaceutical
Therapeutics
$102M23 Feb 2022 San Diego, California, United States

Arkuda Therapeutics

Biotechnology
Health Care
Pharmaceutical
Therapeutics
$64M10 Feb 2022 Cambridge, Massachusetts, United States

SanReno Therapeutics

Biotechnology
Therapeutics
$40M30 Nov 2021 Beijing, Beijing, China

HotSpot Therapeutics

Biopharma
Biotechnology
Health Care
Life Science
Pharmaceutical
Therapeutics
$100M29 Nov 2021 Cambridge, Massachusetts, United States

Evommune

Biotechnology
Life Science
$83M09 Sep 2021 California, United States

Vigil Neuroscience

Biotechnology
$90M18 Aug 2021 Cambridge, Massachusetts, United States

Oculis

Biotechnology
Health Care
Pharmaceutical
$57M04 May 2021 Iceland, Iceland

Exscientia

Artificial Intelligence
Biotechnology
Health Care
Pharmaceutical
$225M27 Apr 2021 Oxford, England, United Kingdom

Exscientia

Artificial Intelligence
Biotechnology
Health Care
Pharmaceutical
$225M20 Apr 2021 Oxford, England, United Kingdom
News
Obsidian Therapeutics Closes $115M Series B Financing

– Obsidian Therapeutics, Inc. is a Cambridge, Mass.-based biotechnology company pioneering engineered cell and gene therapies.
– The company closed a $115m Series B financing.
– The round was led by The Column Group Crossover Fund (TCGX) with participation from RA Capital Management, Surveyor Capital (a Citadel company), Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal BioVenture Partners, Samsara BioCapital, and Soleus Capital, and existing investors Atlas Venture, Vertex Ventures HC, Amgen Ventures, and Bristol Myers Squibb.
– Proceeds from the financing will be used to drive Obsidian’s lead tumor infiltrating lymphocyte (TIL) program, cytoTIL15, into the clinic and to first clinical data for the treatment of metastatic melanoma. In addition, the company plans to rapidly expand cytoTIL15 into multiple other solid tumor types and to advance its commercial manufacturing build.

Vigil Neuroscience Completes $90 million Series B Financing to Advance a Pipeline of Microglia-targeted Medicines to Treat Rare and Common Neurodegenerative Diseases

– Vigil Neuroscience, a biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, announced the completion of a $90m Series B financing to further advance Vigil’s proprietary pipeline of microglia-targeted medicines for the treatment of neurodegeneration.
– The financing was led by Vida Ventures with participation from existing investors Atlas Venture, Northpond Ventures and Hatteras Venture Partners as well as new investors including Surveyor Capital (a Citadel company), Cormorant Asset Management, Invus, OrbiMed, Rock Springs Capital, Deep Track Capital, Logos Capital, Pivotal bioVenture Partners, and Lightstone Ventures.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Pivotal bioVenture Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: